Adlai Nortye (ANL) Accounts Payables (2022 - 2026)
Adlai Nortye (ANL) posted quarterly Accounts Payables of $12.6 million for Q4 2025, up 24.56% year-over-year from $10.1 million in Q4 2024, and up 30.58% quarter-over-quarter from $9.7 million in Q2 2025.
Analysis
Adlai Nortye (ANL) Accounts Payables (2022 - 2026) Analysis & Trends
Adlai Nortye (ANL) has reported Accounts Payables for 4 consecutive years, with $12.6 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Accounts Payables rose 24.56% year-over-year to $12.6 million; the TTM figure through Dec 2025 stood at $12.6 million (up 24.56% YoY), while the FY2025 annual figure was $12.6 million, up 24.56% from the prior year.
- Accounts Payables advanced to $12.6 million in Q4 2025 per ANL's latest filing, from $9.7 million in the prior quarter.
- Across five years, Accounts Payables topped out at $14.3 million in Q4 2023 and bottomed at $9.7 million in Q2 2025.
- Historically, Accounts Payables has averaged $11.8 million across 4 years, with a median of $11.8 million in 2024.
- Annual changes were most pronounced in 2024 — Accounts Payables declined 29.29% — and 2025, when it gained 24.56%.
- Adlai Nortye's Accounts Payables stood at $13.1 million in 2022, then rose by 9.54% to $14.3 million in 2023, then slipped by 29.29% to $10.1 million in 2024, then advanced by 24.56% to $12.6 million in 2025.
- Business Quant data shows ANL's Accounts Payables at $12.6 million in Q4 2025, $9.7 million in Q2 2025, and $10.1 million in Q4 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 167.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 88.42 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 470.30 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 108.02 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 35.57 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 428.93 Mn |
| 10 | Adlai Nortye | 500.08 Mn | 268.19 Mn | - | 4.61 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 4.61 Mn |
| Dec 31, 2025 | 12.64 Mn |
| Jun 30, 2025 | 9.68 Mn |
| Dec 31, 2024 | 10.15 Mn |
| Jun 30, 2024 | 11.00 Mn |
| Dec 31, 2023 | 14.35 Mn |
| Dec 31, 2022 | 13.10 Mn |